| INTRODUCTION
Crohn's disease (CD) is a chronic relapsing inflammatory bowel disease (IBD) of multifactorial aetiology. It has long been identified that patients with IBD have altered body composition during various disease states. [1] [2] [3] This may be due to a multitude of factors such as malnutrition, a catabolic state and malabsorption which alters body composition. 4, 5 Decreased muscle mass or myopenia is prevalent in patients with CD who are in clinical remission. 1 Furthermore, recent studies have shown that body composition influences outcomes in
Crohn's patients with surgery, attracting more post-operative complications. 6, 7 CD phenotype may also play a role in a patient's body composition with luminal CD contributing to decreased lean body mass. 8 Anti-TNF therapy forms the backbone of treatment in patients with moderate to severe Crohn's disease. However, it has a primary nonresponse rate of 10%-30% in clinical practice and secondary loss of response rate of about 5% per patient-year, 9 ,10 potentially exposing patients to side-effects with minimal therapeutic benefit. BMI has been linked to primary nonresponse in observational cohort studies and may be due to pharmacokinetic effects on drug levels.
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Skeletal muscle and adipose tissue have demonstrated either pro or anti-inflammatory properties through the release of cytokines. 12 The recent discovery of the role of creeping fat in IBD via Substance P by releasing Il-17 in pre-adipocytes and increasing Il-17A receptors in the IBD colon, has shown the important role of visceral adiposity in the development of inflammatory bowel disease. 13 It has been observed that inter-patient variability of anti-TNF levels was poorly associated with BMI, but intra-patient anti-TNF levels were stable. 14 However, in a small population of anti-TNF na€ ıve patients, the body composition parameters that correlated with anti-TNF trough levels were body surface area, fat-free mass index (FFMI) and skeletal muscle index (SMI). 15 Therefore, we hypothesised that the composition of a patient's body mass may demonstrate a more refined method of analysis and provide better understanding of the causes of primary nonresponse and secondary loss of response.
We aim to demonstrate that using a validated tool for assessing body composition, we can predict primary nonresponse or secondary loss of response in patients receiving anti-TNF therapy with moderate to severe Crohn's disease using a patient's muscle and fat content.
2 | ME TH ODS 
| Computed tomography image analysis
Images were retrieved from digital storage in the picture archiving and communication system. Computed tomographic image analysis was performed using SLICE-O-MATIC V4.3 software (Tomovision, Montreal, Canada) as described previously. 16 The study was limited to CT
given it was the predominant modality during the study period with 
| RESULTS
Six hundred and fifty patients who were administered their first dose of anti-TNF therapy were included with 250 patients having CT studies prior to their first dose. Of these, 106 patients had CT studies within 6 months of anti-TNF commencement ( Figure 1 ).
Forty-seven of 106 (44%) were male with a median age of 
| Primary nonresponse
There were 26 patients (24.5%) who experienced primary nonresponse. Of these, 15 (57.7%) were myopenic. There were 6 (25%) patients with nonvisceral obesity and 5 (25%) with myosteatosis.
On univariate analysis, presence of myopenia (Odds ratio (OR) Figure 3) . However, none of the body composition factors or biochemistry at induction were associated with secondary loss of response. 
| Pharmacokinetic sub-study
The association between estimated total body fat-free mass and BMI Men were more likely to have a lower fat-free mass in proportion to their BMI than women (P = .05), and thus a larger proportion of men than women were in the highest ranges of anti-TNF per kg fat-free mass. This is demonstrated in Figure 4B .
| DISCUSSION
Myopenia is associated with primary nonresponse to anti-TNF therapy in patients with moderate to severe luminal Crohn's disease.
This study also demonstrates that there is wide variation in body composition profile, thus tailoring medication to each patient is important. This may be due to a multitude of factors including underlying luminal disease causing malabsorption 1, 5, 20, 21 and the interplay between pro-inflammatory and anti-inflammatory cytokines released by adipocytes or muscle. 22, 23 Body composition is important in determining the volume of distribution of medications such as anti-TNF therapy and it is plausible that this contributes to pharmacokinetic failure due to inadequate dosing. 24 The mechanisms of primary nonresponse as laid out in a review by Ding et al., include pharmacokinetic, pharmacodynamic or immunogenic failure. 10 Following administration, anti-TNF is distributed centrally to extracellular fluid with a volume of distribution of about 0.1 l/kg. 25, 26 The most likely explanation for nonresponse due to myopenia would be inadequate dosing due to increased clearance or decreased uptake resulting in pharmacokinetic failure.
Unfortunately, drug levels were not available at the time of this study but would be an area of future research. Furthermore, taking into account patient's disease phenotype and severity at time of induction, myopenia was associated with primary nonresponse to anti-TNF therapy. However secondary loss of response was not associated with any of the body composition factors. Rather, combined immunomodulator at time of induction was protective of secondary loss of response as shown in Figure 3 , which complements the existing literature. 27, 28 The lack of association may be due to anti-TNF therapy improving inflammatory myopenia after induction therapy as demonstrated in a prospective observational study. 29 The finding that combination therapy with an immunomodulator and anti-TNF is protective of secondary loss of response demonstates that this may prevent immunogenic failure through the inhibition of antibody formation. 27 Intra-individual variation in anti-TNF level is dramatic given that anti-TNF therapy is absorbed and distributed centrally throughout the body. 30 Data from oncology utilising a similar pharmacokinetic study with FFM as the volume of distribution of chemotherapy drugs rather than body surface area, showed similar variations in drug level within the cohort. 19 Therefore, the composition of an individual's mass is important in determining correct dosing. Body surface area has been shown to have a negative correlation with adalimumab trough levels and is correlated to muscle content (FFMI: r = À.494, P = .045), but not with fat parameters (BFMI: r = À.099 P = .708). 15 Our study in this large cohort confirms these findings, as pharmacokinetic failure may result from myopenia, but no correlation was identified with visceral obesity. The median albumin in our cohort was 37 g/L (IQR 37-40). Our finding that albumin ( <30 g/L)
was associated with primary nonresponse on univariate analysis (OR 0.94; 0.88-0.99, P = .04) also supports the current literature and demonstrates that patients with severe disease may require higher doses to induce remission.
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A consistent finding is that there is loss of lean mass with preserved fat mass. 3 Other possible causes of pharmacokinetic failure may be due to increased drug clearance in patients with higher ( >120 kg) and low ( <40 kg) body weight. 31 Our hypothetical scenario of anti-TNF infusion at a dose of 5 mg/kg when taking into account patient's lean body mass revealed six-fold variation in anti-TNF per kg fat-free mass.
T A B L E 3 Primary nonresponse rates to anti-TNF therapy with each quartile of muscle mass with correlation between lean skeletal muscle index and primary nonresponse One possible explanation for lower muscle mass in CD patients is poor nutritional status. In CD, selected micro and macronutrient deficits, loss of body cell mass and muscle strength are frequent even in remission. 4 In a recent publication by van Langenberg et al, 12 there was a 54% lower phosphorylated:total Akt ratio in muscle samples (P <.05) showing a key decrease in the hypertrophy signalling pathway. However, there were no differences in the atrophy signalling targets MuRF-1 or atrogin-1 mRNA protein levels.
Therefore, the rate of replacement of muscle protein may not be adequate to meet the rate of muscle proteolysis in an inflammatory state. 32 In an in vivo animal model, it was shown that colitis increased albumin synthesis at the expense of muscle protein synthesis in macronutrient-restricted piglets. 33 Demonstrating that myopenia is prevalent in Crohn's patients is important for its functional effects on patients including weakness The main limitation of this retrospective observational study design is the inability to determine causality. Other clinical parameters such as smoking could not be obtained given the retrospective nature of the data. Also, therapeutic drug monitoring was not available during the time of this study and therefore the end-point of anti-TNF cessation or switch was used as the definition of secondary loss of response. However, myopenia was identified to be a significant factor after adjusting for biomarkers of disease severity such as CRP and albumin. Although albumin may be a marker for chronic disease, this was not seen to be significant on multivariable analysis.
Furthermore, this work will lead onto further studies detailing adequate dosage adjustments which may be made with body composition markers as the main determinant rather than body mass index and with the measurement of drug levels, which will have implications for therapy. Potentially, measuring body composition in patients prior to anti-TNF therapy may allow for a more accurate dosing paradigm in personalising medical therapy.
| CONCLUSION S
Body composition is important in analysis of patients with Crohn's disease. Our study has identified myopenia prior to anti-TNF admin- 
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